Cargando…
Network pharmacology and experimental verification reveal the mechanism of safranal against glioblastoma (GBM)
INTRODUCTION: Safranal is an active component of the traditional Tibetan medicine (TTM) saffron, which has potential anticancer activity. METHODS AND RESULTS: Here, we studied the therapeutic effect and mechanism of safranal on GBM. CCK-8, GBM-brain organoid coculture experiments and 3D tumour spher...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509474/ https://www.ncbi.nlm.nih.gov/pubmed/37736545 http://dx.doi.org/10.3389/fonc.2023.1255164 |
Sumario: | INTRODUCTION: Safranal is an active component of the traditional Tibetan medicine (TTM) saffron, which has potential anticancer activity. METHODS AND RESULTS: Here, we studied the therapeutic effect and mechanism of safranal on GBM. CCK-8, GBM-brain organoid coculture experiments and 3D tumour spheroid invasion assays showed that safranal inhibited GBM cell proliferation and invasion in vitro. Network pharmacology, RNA-seq, molecular docking analysis, western blotting, apoptosis, and cell cycle assays predicted and verified that safranal could promote GBM cell apoptosis and G2/M phase arrest and inhibit the PI3K/AKT/mTOR axis. In vivo experiments showed that safranal could inhibit GBM cell growth alone and in combination with TMZ. CONCLUSION: This study revealed that safranal inhibits GBM cell growth in vivo and in vitro, promotes GBM cell apoptosis and G2/M phase arrest, inhibits the PI3K/AKT/mTOR axis and cooperate with TMZ. |
---|